Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally
"The granting of this patent further expands
"Obtaining this new patent provides additional intellectual property coverage for the unique and novel features of our Target Selector™ platform, featuring our antibody cocktail and microchannel capture technologies for CTCs and other rare cells of interest," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, the utility of our intellectual property protections, and our ability to expand opportunities to generate revenues in territories outside the U.S., such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Contact:
LHA Investor Relations
Jcain@lhai.com
(310) 691-7100
View original content:http://www.prnewswire.com/news-releases/biocept-awarded-patent-in-china-for-its-circulating-tumor-cell-platform-expanding-intellectual-property-estate-to-33-issued-patents-globally-300857051.html
SOURCE